|
|
||||||||
-Activated Endothelium Under Flow In Vitro1



*
Vascular Research Division, Departments of Pathology, Brigham and Womens Hospital and Harvard Medical School, Boston, MA 02115;
Department of Immunology and Microbiology, Northwestern University School of Medicine, Chicago, IL 60611; and
Drug Discovery Group, Genetics Institute, Cambridge, MA 02140
| Abstract |
|---|
|
|
|---|
-activated HUVEC. KPL1, an
adhesion-blocking mAb directed against the tyrosine sulfate motif of
PSGL-1, abolished monocyte-adhesive interactions with P-selectin, but
only partially blocked monocyte interaction with E-selectin. Further
analysis showed that on E-selectin, KPL1 blocked only secondary (i.e.,
monocyte/monocyte) interactions, but did not block primary (i.e.,
monocyte/E-selectin) interactions, with secondary adhesion accounting
for 90% of the total adhesive interactions on either E- or P-selectin.
On cytokine-activated HUVEC, monocytes initially attached and formed
linear strings of adherent cells, which involved both primary and
secondary adhesion. PSGL-1 or L-selectin mAb reduced string formation,
and the combination of PSGL-1 and L-selectin mAb prevented monocyte
strings and inhibited 86% of accumulation. Monocyte attachment and
rolling on purified adherent monocytes were also critically dependent
on PSGL-1 on the adherent monocytes. These studies document that
secondary interactions between monocytes, mediated by PSGL-1, are
crucial for monocyte initial attachment, rolling, and accumulation on
activated endothelium under laminar shear flow. | Introduction |
|---|
|
|
|---|
Recent studies have identified leukocyte structures that present carbohydrate ligands for recognition by E- and P-selectins (reviewed in 7 . A glycoprotein described initially as a ligand for P-selectin, termed PSGL-13 (8), was cloned and demonstrated subsequently to interact with both E- and P-selectin in some in vitro assays. PSGL-1 is a mucin-like homodimer consisting of two disulfide-linked subunits with an apparent molecular mass of 120 kDa each. PSGL-1 undergoes posttranslational modifications, including cleavage by paired basic converting enzyme, sulfation on one or more of the three tyrosines located in the anionic N-terminal region, and significant glycosylation, depending upon the enzymatic activities of different leukocyte cell lineages. PSGL-1 is expressed by essentially all blood leukocytes, including neutrophils, monocytes, and lymphocytes, and is glycosylated extensively with N-linked glycans and closely spaced O-linked glycans, a portion of which are modified with sialyl Lewisx epitopes (9) and the HECA452 Ag (10, 11). In assays performed under flow, PSGL-1 has been reported to mediate adhesion of human neutrophils (12, 13) and T lymphocytes (13, 14, 15) to P-selectin and to be required for optimal attachment to E-selectin (16). L-selectin is expressed on neutrophils, monocytes, and most lymphocytes, and also has been proposed to present carbohydrate ligands to E- and P-selectin. Similar to PSGL-1, L-selectin carries sialyl Lewisx-type structures and is localized on the tips of microvilli (17). However, more recent studies in vitro suggested that L-selectin does not serve as a ligand for E- or P-selectin during leukocyte adhesion to endothelium; rather, it is more likely that L-selectin serves to mediate leukocyte/leukocyte (interleukocyte) adhesion, which can greatly amplify leukocyte adhesion to and accumulation on endothelium in vitro (18).
Recent studies report that L-selectin participates in interleukocyte
adhesion under flow, which promotes rapid and efficient adhesion of
neutrophils (18, 19) and
/
T cells (20) to cytokine-activated
endothelium. L-selectin on newly arriving leukocytes interacts with
multiple ligands on leukocytes already stably adherent on the HUVEC
surface, and thus mediates formation of strings of rolling cells (18)
that greatly enhance leukocyte accumulation under defined laminar flow
conditions. The ability of adherent leukocytes to form strings on
endothelium or isolated adhesion molecules has been noted earlier for
both neutrophils (21) and monocytes (5, 6). Subsequently, PSGL-1 has
been shown to serve as one of the ligands for L-selectin to mediate
neutrophil/neutrophil interactions (22), with blocking mAb inhibiting
60% of these interactions. In addition, several less well-defined
leukocyte structures have been described to act as ligands for
L-selectin, and thus amplify leukocyte capture on various substrates
(18, 22). While the role of L-selectin in monocyte/monocyte (18) and
monocyte/HUVEC interactions (5, 6) under flow has been explored, the
role of PSGL-1 has yet to be examined directly for monocyte/monocyte
and monocyte/endothelial adhesive (e.g., E- and P-selectin)
interactions under flow conditions.
In this study, we have examined in detail the adhesive interactions of
human blood monocytes with TNF-
-activated human endothelial cell
monolayers, as well as the inducible endothelial cell adhesion
molecules E-selectin and P-selectin, under conditions likely to
simulate blood flow in microvessels in vivo. The experiments using mAb
KPL1, which recognizes a sulfated N-terminal epitope (9, 13),
demonstrate that PSGL-1 is the predominant monocyte ligand for
P-selectin, but not E-selectin, and that PSGL-1, in conjunction with
L-selectin, mediates crucial adhesive interactions for both
monocyte/monocyte and monocyte/HUVEC adhesion, suggesting that
targeting these adhesion pathways may provide beneficial therapies in
chronic vascular disease settings.
| Materials and Methods |
|---|
|
|
|---|
Human rTNF-
was obtained from Genentech (S. San Francisco,
CA) and was free of detectable endotoxin, as reported previously (6). A
concentration of 20 ng/ml for 4 to 6 h gave optimal expression of
VCAM-1, E-selectin, P-selectin, and ICAM-1 on HUVEC (6). HBSS with and
without Ca2+ and Mg2+, M199,
-media, and
HEPES were obtained from BioWhittaker (Walkersville, MD). FBS was
obtained from HyClone (Urem, UT). All other chemicals were of the
highest grade available from Baker Chemical (Phillipsburg, NJ). All
buffers that came in contact with monocytes were purchased
commercially, and all subsequent solutions were from sterile disposable
plasticware to minimize endotoxin contamination.
Monoclonal Abs
A function-blocking murine mAb, KPL1 (IgG1, used as purified IgG at 20 µg/ml), recognizes the tyrosine-sulfated motif at the N-terminal portion of human PSGL-1, as detailed (13). Murine mAb directed to L-selectin (LAM1-4 (blocking), LAM1-14 (nonblocking), both IgG1) (23) were purified IgG (used at 10 µg/ml). Function-blocking mAb HEL3/2 (IgG1) (24) recognizes human E-selectin and was used as IgG (10 µg/ml). Function-blocking mAb HPDG2/3 (IgG1) recognizes P-selectin (8) and was used as IgG (10 µg/ml). Control mAb W6/32 (IgG2a) recognizes human class I Ag and is expressed at high levels on HUVEC and leukocytes, and does not alter leukocyte adhesion to cytokine-activated endothelium (6).
Isolation and culture of endothelial cells and preparation of adhesion molecule-coated substrates
HUVEC were isolated from two to five umbilical cord veins,
pooled, and established as primary cultures in M199 containing 20% FBS
(5). Primary HUVEC cultures were passed serially (6) at a 1:3 split
ratio and maintained in M199 containing 10% FBS, endothelial cell
growth factor (50 µg/ml; Biomedical Technologies, Stoughton, MA),
porcine intestinal heparin (100 µg/ml; Sigma, St. Louis, MO), and
antibiotics. For use in the flow apparatus, HUVEC (passage 1) were
plated at 80% confluence on 25-mm circular glass coverslips (No. 1
thickness; Thomas Scientific, Swedesboro, NJ) previously precoated
overnight with human fibronectin (2 µg/cm2). HUVEC were
allowed to reach confluence and were used in experiments within 24 and
72 h. CHO cells stably transfected with P-selectin (CHO-P) or
E-selectin (CHO-E) have been reported previously (8). CHO-E and CHO-P
cells were cultured in
-medium with 10% dialyzed FBS (HyClone) and
plated on glass coverslips, as detailed above for HUVEC monolayers, and
used when they achieved
90% confluence, as detailed earlier (25).
Purified recombinant human E-selectin and P-selectin molecules have
been described (8, 26) and were adsorbed to 25-mm-diameter glass
coverslips using a stock solution of 10 µg/ml in 10 mM sodium
bicarbonate, pH 9.5 (9, 27). Just before use in flow experiments, the
selectin-coated coverslips were incubated at ambient temperature with
1% Tween-20 in DPBS containing Ca2+ and Mg2+
for 1 min to reduce nonspecific cell adhesion (21, 27).
Monocyte isolation
Human monocytes were isolated from platelet pheresis residues by centrifugation on density gradients (LSM; Organon Teknika, Durham, NC), followed by counterflow centrifugation elutriation (28). Monocyte suspensions were >91% pure with 6 to 8% lymphocyte, <2% granulocyte, and essentially no platelet contamination, as determined by light scatter (FACScan; Becton Dickinson, Mountain View, CA) and cell surface Ag analysis with mAb directed to CD14, CD41, and CD61, and P-selectin (5, 6). L-selectin surface expression was not significantly changed following elutriation, and CD18 expression increased minimally in 10 separate preparations that were analyzed (5). Thus, monocytes isolated by this technique had minimal alterations in surface adhesion molecules that are sensitive markers for activation, implying that these cells were minimally perturbed. Isolated monocytes were resuspended in warm perfusion buffer (DPBS containing 0.75 mM Ca2+, 0.75 mM Mg2+, and 0.2% HSA) and were used immediately in flow studies. All buffers and reagents contained <10 pg/ml of endotoxin (E-toxate kit; Sigma).
HUVEC/leukocyte interactions in a parallel plate flow chamber
The parallel plate flow chamber used in this study has been
described in detail (5). Defined levels of flow are applied to the
HUVEC monolayer by drawing perfusion media through the channel via a
syringe pump (model 44; Harvard Apparatus, Natick, MA). Saturating
levels of each mAb were used for all incubations and also were added in
the perfusion buffer. The entire time period of monocyte perfusion was
videotaped, and accumulation was determined from videotape at 8 to 10
min of perfusion by enumerating adherent cells in six random fields.
Monocytes were considered to be adherent after 20 s of stable
contact with the monolayer (6). Formation of strings of adherent
monocytes and accumulation on HUVEC monolayers or isolated E-selectin
and P-selectin coverslips was assessed during the first 4 min of
monocyte perfusion using a x20 objective to visualize the entire field
of view for contact between incoming monocytes and the adhesive
substrates. We used the same strategy as Alon et al. (18) to identify
primary and secondary adhesion (or tethers) on substrates. Strings of
adherent monocytes at the end of 4 min were identified first, and then
the tape was replayed frame by frame to identify and track incoming
monocytes that either attached to substrate surface without previous
interactions (primary adhesions) with adherent monocytes, or monocytes
that attached to HUVEC via interactions with previously adherent
monocytes (secondary adhesions). Primary and secondary adhesions
reported in Figure 6
were determined in 15-s time periods over the
first few minutes of perfusion to determine the kinetics, or over a
4-min time period, as described for Figure 3
. All fields of observation
were located as far upstream toward the inlet port as possible to
enable the viewers to track the history of the incoming monocyte to
allow precise identification of primary and secondary cell adhesions.
Typically, two or three blinded observers viewed the tape to determine
primary and secondary adhesion, and these data were pooled to give the
mean and SDs.
|
|
Monocyte-adhesive substrates were prepared using a modification of a previous report (22). Circular 25-mm glass coverslips were immersed in 100% ethanol and air dried, and a 1-cm-diameter region delineated with marker was washed three times with DPBS. After washing, 40 µl of a monocyte suspension (107 cells/ml in perfusion buffer) was placed on the washed area and incubated for 7 min at ambient room temperature. The region of adherent cells was immersed in freshly prepared 0.25% paraformaldehyde in DPBS without Ca2+ and Mg2+ (5 min) at room temperature, washed extensively with perfusion buffer, and blocked (10 min) with 1% HSA-DPBS without Ca/Mg2+ containing 0.2% sodium azide. Coverslips were used immediately in flow studies.
Statistics
Data were analyzed by one-way analysis of variance, followed by
Tukey analyses of multiple comparisons for multiple mAb treatments in
Figures 1
, 2
, and 4
(Minitab for Windows, release 10; Minitab, State
College, PA). Significance was set to 0.05.
|
|
|
| Results |
|---|
|
|
|---|
To evaluate the role of PSGL-1 in monocyte attachment to
E-selectin or P-selectin under flow at 1.8 dynes/cm2,
function-blocking studies were conducted using monolayers of CHO cells
stably transfected with full-length human E-selectin or P-selectin
(CHO-E and CHO-P, respectively). Murine mAb, KPL1, has been shown
previously to recognize the N-terminal tyrosine sulfation motif of
mature PSGL-1, which is expressed on human circulating blood leukocytes
(13). As shown in Figure 1
(bottom
panel), monocytes attached and rolled on CHO-P cell monolayers,
and pretreatment of monocytes with anti-PSGL-1 mAb (KPL1) reduced
significantly monocyte interactions (50% inhibition) as compared with
control anti-HLA class I (mAb W6/32). Blockade of CHO-P cells with
anti-P-selectin mAb (HPDG2/3) totally blocked monocyte
interactions. Anti-L-selectin mAb (LAM14) also reduced adhesion, and
if combined with anti-PSGL-1, reduced adhesion by 92%. Blocking
studies performed with CHO-E monolayers revealed that KPL1 treatment of
monocytes also reduced adhesion (45% inhibition) as compared with
control mAb to class I (W6/32). mAb LAM14 inhibited interactions by
82%, and the combination of KPL1 and LAM14 mAb blocked most of the
interactions (91% inhibition). As a control, anti-E-selectin mAb
(HEL3/2) totally inhibited all monocyte interactions. These data
suggest that PSGL-1 can serve as a ligand for both E- and P-selectin,
and are quite distinct from our recent findings that KPL1 mAb totally
blocked all neutrophil and peripheral blood T cell adhesion to CHO-P,
but had no effect on interactions with CHO-E monolayers (13).
Leukocyte/leukocyte interactions, which occur via L-selectin on
the incoming leukocyte binding to L-selectin ligands on already
adherent leukocytes, can lead to leukocyte adhesion independent of any
contact with the purified adhesion molecules E-selectin and P-selectin
(18, 20, 29). To distinguish between the two possibilities, we
attempted to determine the contributions of L-selectin and PSGL-1 to
initial monocyte/E-selectin or P-selectin interactions (primary
adhesions, as originally described by Alon et al. (18)) or
monocyte/monocyte interactions (secondary adhesions). However, because
of the varied topology of the CHO cell monolayers, we were not able to
confidently track monocyte trajectories across the monolayer surface or
to clearly distinguish primary and secondary adhesions. As an
alternative strategy, purified recombinant E-selectin or P-selectin
molecules were adsorbed on glass coverslips to overcome the topology
issue. Using this strategy, monocyte interaction with P-selectin on
coverslips is ablated with anti-PSGL-1 mAb (Fig. 2
, bottom panel). The
specificity is demonstrated by the ability of anti-P-selectin mAb
to totally block monocyte interactions, while control anti-class I
(mAb W6/32) is without effect. This result demonstrates that the
epitope recognized by mAb KPL1 on PSGL-1 is essential for binding to
P-selectin under flow conditions. Interestingly, mAb KPL1 also reduced
monocyte interactions with E-selectin by 62% as compared with W6/32
mAb control (Fig. 2
, top panel). Careful analysis of the
videotapes from these studies revealed that KPL1 mAb inhibited
monocyte/monocyte interactions (i.e., secondary capture), but not
primary adhesion to E-selectin (Fig. 3
).
In contrast, we found no evidence in any experiment for monocyte
binding to P-selectin in the presence of KPL1 mAb. Given published
reports (18, 22), we conclude that PSGL-1 expressed on monocytes
already adherent to E-selectin acts as a ligand for incoming freely
flowing monocytes (also see below section).
KPL1 mAb blocks monocyte adhesion to TNF-
-activated HUVEC under
flow at 1.8 dynes/cm2
Figure 4
shows that monocyte
adhesion to media-treated HUVEC monolayers is negligible, whereas
adhesion to 6-h TNF-
-activated HUVEC monolayers is increased by 12-
to 15-fold, which is in line with our previous report (6). Pretreatment
of monocytes with mAb KPL1 dramatically reduced adhesion (72%
inhibition), as assessed after 10 min of leukocyte perfusion (Fig. 4
).
This level of inhibition is significantly more than one would expect if
PSGL-1 interacted solely with P-selectin expressed on TNF-
-activated
HUVEC, because F(ab')2 preparations of anti-P-selectin
HPDG2/3 mAb block only 30% of monocyte adhesion (data not shown and
(6)). Given the above data that L-selectin and PSGL-1 can mediate
monocyte/monocyte interleukocyte adhesion on both E- and P-selectin,
and recent reports demonstrating PSGL-1 interacts with both L-selectin
and P-selectin (13, 22), we compared the effect of anti-L-selectin
mAb alone and in combination with anti-PSGL-1 mAb. LAM1-4, a
function-blocking anti-L-selectin mAb, reduced monocyte adhesion
(75% inhibition) to level similar to anti-PSGL-1 (Fig. 4
). Control
nonblocking anti-L-selectin mAb LAM1-14 or control anti-class I
(mAb W6/32), which is expressed on both monocytes and HUVEC, did not
alter adhesion. The combination of mAb KPL1 and LAM1-4 blocked better
than either alone (p < 0.015;
n = 4 paired experiments), and reduced monocyte
adhesion by 86%, as compared with the combination of nonblocking
control mAb (W6/32 + LAM1-14). Based on the results above showing that
monocytes form interleukocyte adhesions very well on both P- and
E-selectin, we assessed the role of PSGL-1 and L-selectin in this
process of monocyte accumulation on monolayers of E- and P-selectin and
cytokine-activated HUVEC.
After 4 min of monocyte perfusion across 6-h TNF-
-activated HUVEC,
examination of monocyte interactions with the apical endothelial cell
surface revealed that freely flowing monocytes often collided with and
momentarily bound to already adherent monocytes, and then subsequently
traveled downstream and bound to other already adherent monocytes, or
stably arrested on the endothelial surface. This resulted in the
formation of multiple linear strings of rolling and adherent monocytes
(data not shown). The exact same process has been detailed for
neutrophils and
ß T cells on a variety of substrates (unpublished
observations, F. W. Luscinskas; and (18, 19, 20, 22)), and we have
reported this for purified human monocytes interacting with IL-4- or
TNF-
-activated HUVEC monolayers (5, 6). At later time points (8 min
of perfusion), the linear strings of adherent monocytes increased in
size (length and width) and evolved to larger foci of adherent/rolling
monocytes that could be clearly distinguished using a x40 phase
objective (Fig. 5
). The shape of these
foci is broader after 8 min with smaller satellite strings, identified
with arrows, branching out from the initial string (Fig. 5
, A and B, arrows identify satellite strings). In
Figure 5
, the fluid flow is from right to left.
Preincubation of monocytes with control nonblocking L-selectin mAb
(LAM1-14) had no effect (Fig. 5
B). In contrast,
anti-PSGL-1 mAb (Fig. 5
C) or anti-L-selectin mAb
(not shown) blocked most string formation (arrows identify single,
adherent, and/or transmigrated monocytes). When monocytes were
preincubated with both function-blocking mAb (LAM1-4 and KPL1), no
monocyte strings were observed (Fig. 5
D; n =
4 separate experiments). Interestingly, the pattern of monocyte
accumulation after blockade of both L-selectin and PSGL-1 was
essentially random when compared with accumulation with control mAb.
|
PSGL-1 is the predominant L-selectin ligand on adherent monocytes that supports monocyte interleukocyte rolling under flow
To further understand the molecular interactions underlying
monocyte capture under flow at 2 dynes/cm2, experiments
were performed with mAb to PSGL-1 and L-selectin using monolayers of
purified adherent monocytes. Monolayers of adherent monocytes were
prepared and fixed with 0.25% paraformaldehyde to preserve their
round, unactivated morphology and maintain their adhesion to the glass
surface, and to prevent loss or redistribution of L-selectin and PSGL-1
(30, 31, 32). Perfusion of freshly isolated monocytes across monolayers of
fixed monocytes led to a steady flux of rolling or transiently attached
monocytes that were enumerated easily. Few, if any, monocytes adhered
longer than 2 s, which is quite different from monocyte behavior
on purified E- and P-selectin or activated HUVEC reported above. After
3 min of perfusion of media-treated monocytes, a new cohort of
monocytes pretreated with and containing mAb to class I (W6/32 mAb),
followed by cells treated with nonblocking L-selectin mAb (LAM1-14, 10
µg/ml), was added to the reservoir. None of these treatments affected
monocyte/monocyte rolling interactions (Fig. 7
, top
panel). As shown in the middle panel, after 3 min of
perfusion of media-treated monocytes, a cohort of monocytes treated
with PSGL-1 (20 µg/ml of KPL1) was added to the buffer reservoir.
Anti-PSGL-1 mAb consistently and totally blocked monocyte rolling and
transient attachments. After a 3-min washout with media alone (no
monocytes) to remove unbound mAb, a new cohort of W6/32 mAb-treated
monocytes was perfused. As can be seen, monocyte rolling interactions
were essentially ablated by mAb to PSGL-1, but not control mAb (Fig. 7
, compare top to middle
panels). Moreover, monolayers treated with mAb to PSGL-1 did not
support monocyte rolling (5% of control), even after media washout and
perfusion with control mAb-treated monocytes. We next pretreated
monocytes with anti-PSGL-1 mAb and then prepared fixed monolayers
to confirm the effects of PSGL-1 blockade. Although several experiments
were conducted, studies performed using this strategy did not yield
consistent interpretable results.
|
| Discussion |
|---|
|
|
|---|
-activated HUVEC monolayers in vitro. mAb to
PSGL-1 ablates monocyte-adhesive interactions with P-selectin and
partially blocks adhesion to E-selectin. The partial inhibition on
E-selectin monolayers is due to inhibition of monocyte/monocyte
interactions, not monocyte/E-selectin interactions. This result
demonstrates that the epitope recognized by KPL1 mAb, which maps to the
sulfated N-terminal of PSGL-1 (9, 13), is the binding site for
P-selectin, but not for E-selectin. We conclude that human monocytes
bind to E-selectin either by utilizing another site(s) on PSGL-1, or
through other surface-expressed ligands. Remarkably, blockade of either
PSGL-1 or L-selectin alone consistently blocked most adhesion (70 and
76%) to TNF-
-activated endothelial monolayers, and the combination
of mAb was greater than either alone (86%). Based on current
literature, no other leukocyte type exhibits this level of dependence
on the L-selectin and PSGL-1 molecules for adhesion to activated HUVEC.
A similar pattern for mAb inhibition emerges from our studies
with monocyte monolayers. Injection of blocking mAb to PSGL-1 ablated
monocyte interactions within 2 min. Moreover, after washout with media,
monolayers treated with anti-PSGL-1 mAb did not regain the ability
to support rolling of control mAb-treated monocytes (<5% of control),
demonstrating that PSGL-1 is the predominant L-selectin ligand on
adherent monocytes (Fig. 7
, middle panel). The complementary
study with mAb to L-selectin and the above results with PSGL-1 mAb
reveal that L-selectin on incoming monocytes is the predominant
molecule that recognizes PSGL-1 on adherent monocytes. As noted in
Results, we were unable to perform selective pretreatment of
monolayers with mAb to distinguish by a second approach whether PSGL-1
on the monocyte monolayers is the only ligand for L-selectin-mediated
rolling. Because blockade with either anti-PSGL-1 or L-selectin mAb
totally blocked monocyte/monocyte rolling interactions (Fig. 7
) and
more than 90% of interactions on E- and P-selectin substrates (Fig. 3
), other ligands may not be required in this in vitro model.
Previous reports also suggest an important role for PSGL-1 in leukocyte adhesion to endothelium in vivo (33, 34) or endothelial cell adhesion molecules under flow conditions in vitro (13, 22, 35, 36, 37). In vivo studies have found that pretreatment of human neutrophils or the HL60 cell line with blocking mAb (mAb PL1) significantly reduced the leukocyte rolling flux (80% inhibition) and increased leukocyte rolling velocities in rat mesentery venules (34). A second study reported that rat mAb to murine PSGL-1 (mAb 2PH1) blocked 80% of leukocyte rolling in venules of mouse cremaster muscle, and also blocked (80% at 2 h and 60% at 4 h) neutrophil accumulation in a murine model of peritonitis (33). In in vitro studies with neutrophils and eosinophils, PSGL-1 is the predominant ligand for P-selectin and L-selectin, but not for E-selectin (20, 22, 35). Certain T cell subsets also utilize PSGL-1 for recognition of P-selectin under flow (20, 35); however, they also appear to utilize PSGL-1, as well as other sialylated and fucosylated structures, to bind L-selectin under flow (38, 39).
In contrast to PSGL-1, numerous in vivo and in vitro studies have
identified a role for L-selectin in adhesion of monocytes (5, 6, 40, 41), as well as neutrophils (7, 42, 43), eosinophils (36, 44, 45), and

T cells (20) to activated endothelium, but not for PBL (39) or
CD4+ T cell (46) to endothelium. The current results
support the existing paradigm of L-selectin on incoming cells
interacting with PSGL-1 expressed on already adherent monocytes
(secondary adhesion), thus mediating enhanced monocyte accumulation.
Because the combination of anti-L-selectin and anti-PSGL-1 was
slightly greater than either alone, one also can conclude that
L-selectin recognizes an inducible endothelial ligand(s) and/or other
leukocyte ligands, in addition to PSGL-1. Previous studies have also
offered indirect evidence for the existence of an inducible endothelial
cell ligand for L-selectin using a variety of models (40, 41, 47).
Using unfractionated peripheral blood mononuclear leukocytes, monocyte
binding and accumulation on immobilized E-selectin or VCAM-1 were shown
to entail monocyte/monocyte interleukocyte interactions, which were
blocked completely by fucoidin and mAb to L-selectin (DREG56) (18). The
current study confirms and extends these findings. First,
elutriation-purified human monocytes, blocking mAb to PSGL-1, alone and
in combinations with mAb to L-selectin were used, and the analyses
fully documented both primary and secondary adhesion kinetics and the
molecular mechanisms utilized for rolling and accumulating on purified
E- and P-selectin as well as TNF-
-activated HUVEC monolayers. The
requirement for PSGL-1 (and L-selectin) for both initial attachment and
accumulation (Figs. 5
and 6
) is substantially greater for monocytes as
compared with neutrophils and eosinophils (22, 36, 44, 45). The
kinetics of monocyte primary and secondary adhesion in our in vitro
flow model is fit best to quadratic and linear functions, respectively.
Secondary kinetics for monocyte accumulation determined in this study
and for neutrophil accumulation on P-selectin described previously (22)
is fit best to a quadratic function, whereas the primary adhesion
kinetics for either leukocyte type fits best to a linear function (see
Fig. 6
). The analysis of E-selectin and TNF-
-activated HUVEC
monolayers indicates that monocyte primary and secondary kinetics of
accumulation are best fit to quadratic and linear functions,
respectively. We note, however, that the kinetics of monocyte secondary
accumulation on all substrates also could be fit to a linear function,
but the R2 was less favorable. Because of the
rapid accumulation on these substrates, the primary and secondary
adhesion cannot be determined confidently after 4 min.
It is of interest to note that a recent report on human monocyte interactions with IL-1ß-activated HUVEC or L cells stably expressing E-selectin (L-ELAM) under flow at 2 dynes/cm2 did not observe leukocyte string formation (primary adhesion only, no secondary adhesions) (48). In this study, monocytes accumulated at a constant linear rate, and anti-L-selectin treatment of monocytes (DREG56 mAb) did not alter the pattern of monocyte accumulation on IL-1ß-treated HUVEC or L-ELAM. The basis for this discrepancy is not known, but one explanation may reside in the different dimension of the actual flow channel used in these studies or other differences in the design characteristics of the flow chambers.
The importance of secondary capture of leukocytes in vivo remains
to be determined. A recent report (49) indicates that leukocyte capture
by already adherent or rolling leukocytes occurred in vivo, but was not
an important determinant for leukocyte adhesion to endothelium of
venules in the mouse cremaster muscle. Although in this specific model
a small effect for leukocyte-dependent capture was observed, one cannot
discount the role of this mechanism in vivo without further study in
other animal models of acute or chronic inflammation, especially in
response to strong physiologic stimuli (endotoxin, TNF-
, immune
reactions, wounds) or in small microvessels or postcapillary venules,
in which such interactions would be favored. Moreover, the ease with
which monocytes form secondary adhesions, leading to more efficient
capture on HUVEC and endothelial cell adhesion molecules, suggests that
monocytes may use secondary capture to overcome their numerical
disadvantage in blood, as compared with neutrophils and lymphocytes,
and thus preferentially accumulate at sites of inflammation or chronic
immune reactions and atherosclerosis. We speculate that the secondary
interactions described in this study for monocytes could be important
in a setting of a chronic stimulus, such as enhanced adhesion and
intimal accumulation in fatty streaks in atherosclerosis-prone vessels,
in which endothelial leukocyte ligands may be limiting.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Francis W. Luscinskas, Brigham and Womens Hospital, 221 Longwood Avenue, Boston, MA 02115. E-mail address: ![]()
3 Abbreviations used in this paper: PSGL-1, P-selectin glycoprotein ligand-1; CHO, Chinese hamster ovary; CHO-E, Chinese hamster ovary cells stably transfected with E-selectin; CHO-P, Chinese hamster ovary cells stably transfected with P-selectin; DPBS, Dulbeccos PBS. ![]()
Received for publication January 21, 1998. Accepted for publication April 27, 1998.
| References |
|---|
|
|
|---|
activated vascular endothelium under flow in vitro. J. Immunol. 156:326.
/
T cell interactions with E-, P- and L-selectin. J. Immunol. 156:289.[Abstract]
activated vascular endothelium under flow. J. Exp. Med. 181:1179.
-activated vascular endothelium under flow. J. Exp. Med. 181:1179.
This article has been cited by other articles:
![]() |
M. Stefanidakis, G. Newton, W. Y. Lee, C. A. Parkos, and F. W. Luscinskas Endothelial CD47 interaction with SIRP{gamma} is required for human T-cell transendothelial migration under shear flow conditions in vitro Blood, August 15, 2008; 112(4): 1280 - 1289. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Kerr, C. B. Fieger, K. R. Snapp, and S. D. Rosen Endoglycan, a Member of the CD34 Family of Sialomucins, Is a Ligand for the Vascular Selectins J. Immunol., July 15, 2008; 181(2): 1480 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. An, H. Wang, R. Tang, T. Yago, J. M. McDaniel, S. McGee, Y. Huo, and L. Xia P-Selectin Glycoprotein Ligand-1 Is Highly Expressed on Ly-6Chi Monocytes and a Major Determinant for Ly-6Chi Monocyte Recruitment to Sites of Atherosclerosis in Mice Circulation, June 24, 2008; 117(25): 3227 - 3237. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Xu, C. L. Cheng, M. Chen, A. Manivannan, L. Cabay, R. G. Pertwee, A. Coutts, and J. V. Forrester Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis J. Leukoc. Biol., September 1, 2007; 82(3): 532 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sircar, P. F. Bradfield, M. Aurrand-Lions, R. J. Fish, P. Alcaide, L. Yang, G. Newton, D. Lamont, S. Sehrawat, T. Mayadas, et al. Neutrophil Transmigration under Shear Flow Conditions In Vitro Is Junctional Adhesion Molecule-C Independent J. Immunol., May 1, 2007; 178(9): 5879 - 5887. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kipar, H. May, S. Menger, M. Weber, W. Leukert, and M. Reinacher Morphologic Features and Development of Granulomatous Vasculitis in Feline Infectious Peritonitis Vet. Pathol., May 1, 2005; 42(3): 321 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Burns and N. DePaola Flow-conditioned HUVECs support clustered leukocyte adhesion by coexpressing ICAM-1 and E-selectin Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H194 - H204. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Shaw, S. Ma, M. B. Kim, R. M. Rao, C. U. Hartman, R. M. Froio, L. Yang, T. Jones, Y. Liu, A. Nusrat, et al. Coordinated Redistribution of Leukocyte LFA-1 and Endothelial Cell ICAM-1 Accompany Neutrophil Transmigration J. Exp. Med., December 20, 2004; 200(12): 1571 - 1580. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Homeister, A. Daugherty, and J. B. Lowe {alpha}(1,3)Fucosyltransferases FucT-IV and FucT-VII Control Susceptibility to Atherosclerosis in Apolipoprotein E-/- Mice Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1897 - 1903. [Abstract] [Full Text] [PDF] |